Ranbaxy to make drugs in Malaysia, Nigeria

Indian genericsmaker Ranbaxy Laboratories ($RANBXY) is on a bit of an expansion binge. It will build manufacturing plants in Malaysia and Nigeria, reports PBR. The company did not disclose how much it is investing in the two plants, but the Malaysian plant is slated to produce 2.5 billion doses a year, and products from there would be targeted for markets like Singapore and Thailand, the report says. The plant in Nigeria is predicted to open next year and will produce up to 100 million tablets and capsules a year. Ranbaxy is India's largest generics maker and just reported a stellar quarter, with a four-fold increase in earnings tied to new manufacturing plants in India being able to produce generic Lipitor for North America. Story | More

 

Suggested Articles

Cambrex has completed installation of multiple continuous flow reactor platforms at its facility in High Point, North Carolina.

Australia’s Mayne Pharma has opened its $80 million oral solid-dose manufacturing facility in Greenville, North Carolina.

GE is launching its prefab line of drug manufacturing units that will help biopharma companies produce viral vector-based vaccines.